According to a recent LinkedIn post from Cooler Heads, the company is highlighting a patient interview describing an individual’s experience using its Amma scalp cooling system during cancer treatment. The content centers on real-world use of Amma, including why the patient opted for scalp cooling as part of her care journey.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also reiterates that Amma is an FDA-cleared scalp cooling device aimed at minimizing hair loss in adult cancer patients undergoing treatment for solid tumors. For investors, this emphasis on patient stories and regulatory-cleared technology suggests Cooler Heads is focusing on building clinical credibility and patient-centric branding, which could support adoption, reimbursement discussions, and long-term revenue growth in the oncology supportive-care market.